Anti-cancer
Fulvestrant
CAS No.
129453-61-8
A selective estrogen receptor degrader (SERD) used in injectable oncology formulations for hormone-receptor-positive breast cancer.
Fulvestrant is a targeted estrogen-receptor-degrading oncology API manufactured by NovaAcura Biotech under GMP-certified conditions. Full batch documentation and regulatory support are available for global oncology formulation partners.
Applications & Uses
A selective estrogen receptor degrader (SERD) used in injectable oncology formulations for hormone-receptor-positive breast cancer.
Full technical documentation, batch specifications and regulatory support (DMF/CEP) are available on request.
Need This Molecule at Scale?
Get in touch for pricing, lead times and full regulatory documentation.
Get In Touch